GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
US Stock MarketDetailed Quotes
CRBU Caribou Biosciences
- 1.510
- -0.010-0.66%
Close Jan 24 16:00 ET
- 1.500
- -0.010-0.66%
Post 20:01 ET
136.73MMarket Cap-0.91P/E (TTM)
1.550High1.500Low1.05MVolume1.540Open1.520Pre Close1.60MTurnover1.29%Turnover RatioLossP/E (Static)90.55MShares8.33052wk High0.49P/B123.18MFloat Cap1.47052wk Low--Dividend TTM81.58MShs Float32.645Historical High--Div YieldTTM3.29%Amplitude1.470Historical Low1.525Avg Price1Lot Size
Trending Stocks
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day
Caribou Biosciences Stock Forum
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Sunday, 12th January at 7:05 pm
-- CB-010 GALLOP Phase 1 trial initiated in lupus --
-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Sri Ryali appointed chief fi...
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
No comment yet